Citation Report
List of articles citing

10 years into the resurgence of covalent drugs

DOI: 10.4155/fmc-2020-0236
Future Medicinal Chemistry, 2021, 13, 193-210.

#	Paper	IF	Citations
45	Recent advances in the development of covalent inhibitors. *RSC Medicinal Chemistry*, **2021**, 12, 1037-1045	3.5	7
44	Early career research in medicinal chemistry. *Future Medicinal Chemistry*, **2021**, 13, 91-93	4.1	0
43	Prioritization of antimicrobial targets by CRISPR-based oligo recombineering.		0
42	Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1. *Journal of Medicinal Chemistry*, **2021**, 64, 4903-4912	8.3	5
41	Electrophilic Natural Products as Drug Discovery Tools. *Trends in Pharmacological Sciences*, **2021**, 42, 434-447	13.2	5
40	Covalent fragment screening. *Annual Reports in Medicinal Chemistry*, **2021**, 56, 243-265	1.6	0
39	Covalent PROTACs: the best of both worlds?. *RSC Medicinal Chemistry*, **2021**, 12, 1452-1458	3.5	4
38	Mechanism of activation and the rewired network: New drug design concepts. *Medicinal Research Reviews*, **2021**,	14.4	2
37	Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
36	Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL inhibitors for treating COVID-19. *European Journal of Medicinal Chemistry*, **2021**, 228, 114030	6.8	3
35	Welcome to Volume 14 of .. *Future Medicinal Chemistry*, **2021**,	4.1	
34	High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRAS by Intact Protein MS and Targeted MRM.. *Analytical Chemistry*, **2022**,	7.8	1
33	Identification of the first structurally validated covalent ligands of the small GTPase RAB27A.. *RSC Medicinal Chemistry*, **2022**, 13, 150-155	3.5	0
32	Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs.. *Current Opinion in Chemical Biology*, **2021**, 66, 102106	9.7	3
31	Chemical reactivity prediction: current methods and different application areas.. *Molecular Informatics*, **2021**,	3.8	0
30	How neocarcerand Octacid4 self-assembles with guests into irreversible noncovalent complexes and what accelerates the assembly. *Communications Chemistry*, **2022**, 5,	6.3	
29	Inverse Drug Discovery identifies weak electrophiles affording protein conjugates.. *Current Opinion in Chemical Biology*, **2022**, 67, 102113	9.7	1

28	Electrophilic warheads in covalent drug discovery: an overview.. *Expert Opinion on Drug Discovery*, **2022**, 1-10	6.2	7
27	Promising reversible protein inhibitors kept on target.. *Nature*, **2022**,	50.4	1
26	In situ identification of cellular drug targets in mammalian tissue.. *Cell*, **2022**,	56.2	5
25	Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. *Journal of Molecular Biology*, **2022**, 167626	6.5	0
24	Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. *Cells*, **2022**, 11, 1667	7.9	2
23	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. *Cells*, **2022**, 11, 1812	7.9	1
22	Rational identification of small molecules derived from 9,10-dihydrophenanthrene as potential inhibitors of 3CLpro enzyme for COVID-19 therapy: a computer-aided drug design approach. *Structural Chemistry*,	1.8	3
21	N-Acylamino Saccharin as an Emerging Cysteine-Directed Covalent Warhead and Its Application in the Identification of Novel FBPase Inhibitors toward Glucose Reduction. *Journal of Medicinal Chemistry*, **2022**, 65, 9126-9143	8.3	
20	Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugs. 13,		
19	Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro.		0
18	Tideglusib Inhibits Pif1 Helicase of Bacteroides sp. via an Irreversible and Cys-380-Dependent Mechanism.		
17	Triazine-Based Covalent DNA-Encoded Libraries for Discovery of Covalent Inhibitors of Target Proteins.		0
16	Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an in silico study. **2022**, 24, 23391-23401		0
15	Illuminating spatial pharmacology with in situ drug imaging. **2022**, 12,		0
14	Mutual leveraging of proximity effects and click chemistry in chemical biology.		1
13	Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices.		1
12	A patent and literature review of CDK12 inhibitors. 1-11		0
11	Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.		0

10	Advanced approaches of developing targeted covalent drugs.	0
9	Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery. **2022**, 15, 1322	0
8	CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery. **2022**, 7, 1891-1905	1
7	Development of selective NLRP3 inflammasome inhibitors. **2023**, 565-582	0
6	Proteome-wide structure-based accessibility analysis of ligandable and detectable cysteines in chemoproteomic datasets.	0
5	HCovDock: an efficient docking method for modeling covalent protein□gand interactions. **2023**, 24,	1
4	Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro.	0
3	Drug discovery: Standing on the shoulders of giants. **2023**, 207-338	0
2	bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements. **2023**, 24, 3525	0
1	Technologies for Direct Detection of Covalent Protein□Drug Adducts. **2023**, 16, 547	0